MRK · News · 20261103N
Acquisition / Partnership / Divestiture
Merck & Co., Inc. · 2026-11-03 · Importance 40 · Surprise 42 · In source text
Lonza agreed to acquire Merck’s CDMO business, although the reported announcement did not disclose a transaction value. The divestiture is intended to sharpen the focus of Merck’s Life Science business sector. Merck’s Life Science sector will continue supplying consumables, technologies and services to pharmaceutical, biotechnology and CDMO customers from discovery through manufacturing.
Key facts
- Merck will purchase $50 million of Personalis common stock, obtaining approximately 16.5% beneficial ownership. source
- AmacaThera and Merck Animal Health announced a collaboration to develop long-acting animal-health formulations using AmacaThera’s AmacaGel hydrogel platform. source
- Merck recommended that shareholders reject Tutanota LLC’s unsolicited mini-tender offer to buy up to 1,000,000 Merck common shares for $65.00 per share. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -0.0% | Merck will purchase $50 million of Personalis common stock, obtaining approximately 16.5% beneficial ownership. |
| revenue | positive | contingent | — | AmacaThera and Merck Animal Health announced a collaboration to develop long-acting animal-health formulations using AmacaThera’s AmacaGel… |